GlassScriptPhysician profile
Lawrence P Landrigan
NPI 1922194596
$12,213.69
in general payments reported to CMS, 2019-2025
28 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,668 · 2022: $2,155 · 2023: $2,563 · 2024: $2,859 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,390.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,197.54 | 2021-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,867.11 | 2021-2025 | |
| Ucb, INC. | $1,157.46 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,058.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $631.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $526.48 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $498.94 | 2021-2025 | |
| Lilly USA, LLC | $398.38 | 2021-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $350.09 | 2021-2025 | Benlysta |
| Janssen Biotech, INC. | $324.41 | 2021-2025 | Tremfya |
| Radius Health, INC. | $224.04 | 2021-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $201.83 | 2023-2025 | Idacio, Tyenne |
| Aurinia Pharma U.S., INC. | $172.60 | 2021-2025 | Lupkynis |
| Organon LLC | $88.31 | 2024-2025 | Hadlima, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $83.90 | 2023-2025 | Orencia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $57.81 | 2023-2024 | Hyrimoz |
| Sobi, INC | $56.77 | 2025 | |
| Antares Pharma, INC. | $52.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.30 | 2023-2024 | Cyltezo |
| Horizon Therapeutics Plc | $43.33 | 2021-2022 | |
| Genentech USA, INC. | $37.26 | 2024-2025 | Actemra |
| Arbor Pharmaceuticals, INC. | $27.01 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $24.25 | 2024 | Monoferric |
| Lundbeck LLC | $23.59 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.00 | 2021 | |
| Kyowa Kirin, INC. | $17.75 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.53 | 2022 | |
| Neurelis, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Landrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.